Dr. Ling Zhang 张玲
Chief Physician
Department of Hepatobiliary and Pancreatic Surgery, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and surgical treatment of tumors in the liver, gallbladder, pancreas, and spleen, including complex procedures such as central large liver cancer resection and pancreaticoduodenectomy.
Dr. Zhang is Deputy Director of the Hepatobiliary and Pancreatic Surgery Department and a master’s supervisor. The doctor performs approximately 800 surgeries annually and leads a national major special project sub-topic. Dr. Zhang has completed two provincial projects, received five Henan Medical Science and Technology Progress Awards, one Henan Science and Technology Progress Award, and holds one national patent. Dr. Zhang has co-authored two medical books and published over 30 papers.
Professional roles
- Member, Liver Cancer Professional Committee, China Anti-Cancer Association
- Executive Vice Chair, Hepatobiliary Professional Committee, Henan Anti-Cancer Association
- Deputy Leader, Hepatobiliary Surgery Group, Henan Medical Association
- Editorial Board Member, Henan Journal of Surgery
Name order: in Chinese the family name comes first (Zhang Ling). Papers usually list the name as Ling Zhang or Zhang L.
Selected publications
36 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2024 (senior author): UCHL5 promotes hepatocellular carcinoma progression by promoting glycolysis through activating Wnt/β-catenin pathway. PubMed 38773433
- Am J Infect Control, 2024 (first author): The second dose of COVID-19 vaccine booster hesitancy among health care workers in China: A multicenter cross-sectional study. PubMed 38007100
- Onco Targets Ther, 2021 (senior author): Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma. PubMed 33658801
- World J Gastroenterol, 2019 (senior author): Insulin-like growth factor 2 mRNA-binding protein 1 promotes cell proliferation via activation of AKT and is directly targeted by microRNA-494 in pancreatic cancer. PubMed 31686763
- Am J Hum Genet, 2015 (first author): Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. PubMed 25839328
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion